Teknova Launches Proprietary AAV-Tek™ Solutions Gene Therapy Product Line to Accelerate the Development of AAV Therapies
02 May 2023 - 10:00PM
Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer
of critical reagents for the research, discovery, development, and
commercialization of novel therapies, vaccines, and molecular
diagnostics, today launched the Company's first proprietary product
line, AAV-Tek™ Solutions, specifically created to address
critical pain points in the AAV gene therapy development workflow.
The first product released in this line – the AAV-Tek AEX Buffer
Screening Kit – is available for purchase today and can save gene
therapy developers months of process development time.
The AAV-Tek AEX Buffer Screening Kit, developed by Teknova’s
Research and Development team, is a proprietary, off-the-shelf
selection of discrete buffers that significantly reduces the time
it takes to find the ideal buffer formulation to optimize the
separation of empty and full capsids during the anion exchange
(AEX) purification step. After conducting a robust design of
experiments with hundreds of AEX runs, including extensive
validation against four critical quality attributes (infectivity,
recovery, purity, and peak separation), Teknova identified and
verified a set of seven equilibration and elution buffers optimized
for use across a variety of upstream workflows, transgenes, and
downstream purification platforms.
“Launching our first proprietary product line, AAV-Tek
Solutions, is a momentous milestone and a direct result of
demonstrating our team's expertise in the end-to-end AAV gene
therapy workflow,” said Stephen Gunstream, Teknova’s President and
Chief Executive Officer. “We repeatedly hear from customers that
separation of capsids is challenging and time consuming, limiting
the pace of innovation, and ultimately the delivery of life
changing therapies to patients. By addressing key bioprocessing
bottlenecks with new, custom products, we can collaborate closely
with our customers to help accelerate breakthroughs. Our first
product, the AAV-Tek AEX Buffer Screening Kit, was created to
optimize the purification process and is one-of-a-kind in the
industry. I’m confident it will be a game-changer for gene therapy
developers.”
By removing the need for repeated and extensive buffer
formulation exploration, the AAV-Tek AEX Buffer Screening Kit can
save gene therapy developers working with AAV2 months in their
development timelines, enabling them to discover novel
breakthroughs faster. Developers are able to seamlessly scale from
process development to clinical production by leveraging Teknova’s
industry-leading modular manufacturing platform, hands-on
scientific and technical support teams, and more than 25 years of
experience in reagents bioprocessing production.
The AAV-Tek AEX Buffer Screening Kit for AAV2 is available today
for purchase via phone, email, or online, and is priced at $1,200.
Additionally, Teknova will release a kit for AAV8 in the coming
months and kits to address additional serotypes later this
year.
For more information about the AAV-Tek AEX Buffer Screening Kit
or to purchase it online, visit http://www.teknova.com/AAV2.
ABOUT TEKNOVATeknova makes solutions possible.
Since 1996, Teknova has been innovating the manufacture of critical
reagents for the life sciences industry to accelerate the discovery
and development of novel therapies that will help people live
longer, healthier lives. We offer fully customizable solutions for
every stage of the workflow, supporting industry leaders in cell
and gene therapy, molecular diagnostics, and synthetic biology. Our
fast turnaround of high-quality agar plates, microbial culture
media, buffers and reagents, and water helps our customers scale
seamlessly from RUO to GMP. Headquartered in Hollister, California,
with over 200,000 square feet of state-of-the-art facilities,
Teknova’s modular manufacturing platform was designed by our team
of scientists, engineers, and quality control experts to
efficiently produce the foundational ingredients for the discovery
and commercialization of novel therapies.
Investor Contacts
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Sara Michelmore
MacDougall Advisors
smichelmore@macdougall.bio
+1 781-235-3060
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
Alpha Teknova (NASDAQ:TKNO)
Historical Stock Chart
From Apr 2024 to May 2024
Alpha Teknova (NASDAQ:TKNO)
Historical Stock Chart
From May 2023 to May 2024